Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Summary

This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Timeline

Start

2016-05-19

Primary completion

2021-12

Completion

2025-12

Publications

• Lambert C, Jamal R, Thebault P, Cocolakis E, Belanger K, Dionne J, Cailhier JF, Le H, Letendre C, Lepage S, Shechtman Y, Lapointe R, Miller WH Jr. A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. Oncoimmunology. 2026 Dec 31;15(1):2631244. doi: 10.1080/2162402X.2026.2631244. Epub 2026 Feb 24.

Drugs

Indications